Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alzheimer Disease
Neuro-Hitech, Inc. Announces Agreement with Numoda Corporation to Progress Development of Huperzine a in Alzheimer's Disease
March 28th, 2008
Neuro-Hitech, Inc. (NASDAQ: NHPI), a New York-based biopharmaceutical company focused on developing innovative drugs for the treatment of neurodegenerative diseases, announced that it had entered into an agreement with Numoda Corporation ("Numoda") pursuant to which Numoda will review the results of Neuro-Hitechs' recently completed Phase II clinical trial of Huperzine A in mild to moderate Alzheimer's disease patients. After completing its review and delivering a report of its findings to Neuro-Hitech, Numoda will assist the Company in interpreting and presenting the results to potential licensing partners, purchasers and/or acquisition or merger candidates. Paul...
Source: Health Business Week (2008-03-28)
|
|
Advertisement |
|
|
|
